BUTTGEREIT F

Last name: BUTTGEREIT F

2011 (v1)

Publication

Metadata-only

Alterations of the hypothalamic-pituitary-adrenal axis in systemic immune diseases - a role for misguided energy regulation.

Straub RH Buttgereit F CUTOLO, MAURIZIO

No description

Uploaded on: April 14, 2023
2005 (v1)

Publication

Metadata-only

Benefit of pregnancy in inflammatory arthritis.

Straub RH Buttgereit F CUTOLO, MAURIZIO

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

Regulation of glucocorticoids by the central nervous system.

CUTOLO, MAURIZIO Buttgereit F Straub R.H.

No description

Uploaded on: April 14, 2023
2010 (v1)

Publication

Metadata-only

Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases.

Straub RH CUTOLO, MAURIZIO Buttgereit F

No description

Uploaded on: March 31, 2023
2005 (v1)

Publication

Metadata-only

Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol.

Straub RH Sarzi Puttini P Atzeni F

No description

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

Low-dose glucocorticoids in rheumatic diseases: introduction.

Pincus T Bijlsma JW Braun J

No description

Uploaded on: May 13, 2023
2005 (v1)

Publication

Metadata-only

The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis.

Buttgereit F Saag KG CUTOLO, MAURIZIO

No description

Uploaded on: March 31, 2023
2021 (v1)

Publication

Metadata-only

Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study.

Santiago T Voshaar M de Wit M

No description

Uploaded on: February 14, 2024
2006 (v1)

Publication

Metadata-only

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Da Silva JA Jacobs JW Kirwan JR

No description

Uploaded on: April 14, 2023
2022 (v1)

Publication

Metadata-only

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.

Hartman L da Silva JAP Buttgereit F

No description

Uploaded on: January 31, 2024
2022 (v1)

Publication

Metadata-only

Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.

Hartman L El Alili M Cutolo M

No description

Uploaded on: February 14, 2024
2018 (v1)

Publication

Metadata-only

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L Rasch LA Klausch T

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 1% of the world population. It has major impact on patients through disability and associated comorbidities. Current treatment strategies have considerably improved the prognosis, but recent innovations (especially biologic drugs and the new class of so-called...

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

Duru N van der Goes MC Jacobs JW

No description

Uploaded on: May 13, 2023
2010 (v1)

Publication

Metadata-only

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.

van der Goes MC Jacobs JW Boers M

No description

Uploaded on: March 31, 2023
2023 (v1)

Publication

Metadata-only

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

Almayalım AAH Boers M Hartman L

Objective: The randomised placebo-controlled GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial evaluated the benefits and harms of prednisolone 5 mg/day added to standard care for 2 years in patients aged 65+ years with rheumatoid arthritis (RA). Here, we studied disease activity, flares and possible adrenal insufficiency after...

Uploaded on: February 13, 2024

BUTTGEREIT F

Recent uploads